Aminergic pharmaceutical compositions and methods
1 Assignment
0 Petitions
Accused Products
Abstract
Pharmaceutical compositions and method using aminergic compounds and complement compounds. Compositions are provided comprising: (a) a subefficacious amount of a non-adrenergic aminergic compound or of an adrenergic antagonist; and (b) a safe and effective amount of a complement compound. Methods are also provided comprising the administration of: (a) a low dose of a non-adrenergic aminergic compound or of any adrenergic antagonist; and (b) a safe and effective amount of a complement compound. Non-adrenergic aminergic compounds can comprise a histaminergic, dopaminergic, muscarinergic, serotoninergic, octopaminergic, or trace aminergic compound. Complement compounds include ascorbates, opioids, polycarboxylic acid chelators, resveratrols, cysteines, substituted derivatives and analogs thereof, and mixtures thereof. Preferred complements include ascorbates, particularly ascorbic acid. Methods include the treatment of: neurological and neural disorders; mood and behavior disorders; cardiac, vascular, and cardiovascular disorders; hypertension, headache; respiratory disorders; gastrointestinal disorders; obesity; asthma, allergy; smooth muscle contraction disorders; nasal or nasopharyngeal conditions; genitourinary disorders; ocular disorders, glaucoma; hormone- or neurotransmitter-release or -secretion disorders.
-
Citations
322 Claims
-
1-277. -277. (canceled)
-
296. A pharmaceutical composition comprising:
-
(a) a subefficacious amount of an aminergic compound; and (b) a safe and effective amount of a complement compound that is any of the resveratrol family members or cysteine family members.
-
-
297. A pharmaceutical composition comprising:
-
(a) a safe and effective amount of a non-adrenergic aminergic compound; and (b) a complement compound selected from the group consisting of hyperpreserving amounts of ascorbates, analogs and substituted derivatives thereof;
safe and effective amounts of morphines, analogs and substituted derivatives thereof;
hyperpreserving amounts of polycarboxylic acid chelators, analogs and substituted derivatives thereof;
hyperpreserving amounts of resveratrol family members, analogs and substituted derivatives thereof;
safe and effective amounts of cysteine family members, analogs and substituted derivatives thereof; and
mixtures thereof. - View Dependent Claims (298, 299)
-
-
300. A method for treating a disorder associated with a non-adrenergic biogenic amine receptor in a human or animal subject, comprising:
-
(a) administering to said subject a low dose of a non-adrenergic aminergic compound; and (b) administering to said subject a safe and effective amount of a complement compound. - View Dependent Claims (301, 302, 303, 304, 305, 306, 307, 308)
-
-
309. A method for treating a disorder associated with a non-adrenergic biogenic amine receptor in a human or animal subject, comprising:
-
(a) administering to said subject a safe and effective amount of a non-adrenergic aminergic compound; and (b) administering to said subject a complement compound selected from the group consisting of hyperpreserving amounts of ascorbates, analogs and substituted derivatives thereof;
safe and effective amounts of opiates, analogs and substituted derivatives thereof;
hyperpreserving amounts of polycarboxylic acid chelators, analogs and substituted derivatives thereof;
hyperpreserving amounts of resveratrol family members, analogs and substituted derivatives thereof;
safe and effective amounts of cysteine family members, analogs and substituted derivatives thereof; and
mixtures thereof. - View Dependent Claims (310, 311)
-
-
312. A method for determining a regimen for regulating a biogenic amine receptor in a human or animal subject, comprising:
-
(a) selecting an aminergic compound useful for regulating said receptor, the aminergic compounds being a non-adrenergic aminergic compound or an adrenergic antagonist compound; and (b) selecting a complement compound; (c) determining the dosage level and frequency of dosing of said aminergic compound for use in regulating said receptor when administered to subjects in the absence of said complement; (d) evaluating the effectiveness of said aminergic compound in regulating said receptor when administered to said subjects in the presence of said complement, as a function of the dosage level of said aminergic compound and the dosage level of said complement; and (e) determining a regimen for regulating said receptor in said subjects by (i) selecting a dose level of said aminergic compound which is determined to be effective in said evaluating step (d) and that is lower than the dosage level determined in said step (c); (ii) selecting a dosage frequency that is determined to be effective in said evaluating step (d) and is longer than the dosage frequency determined in said step (c);
or(iii) both (i) and (ii). - View Dependent Claims (313, 314, 315)
-
-
316. A pharmaceutical composition comprising:
-
(a) a subefficacious amount of an adrenergic antagonist compound; and (b) a safe and effective amount of a complement compound. - View Dependent Claims (317, 318, 319, 320)
-
-
321. A pharmaceutical composition comprising:
-
(a) a safe and effective amount of an adrenergic antagonist compound; and (b) a complement compound selected from the group consisting of hyperpreserving amounts of ascorbates, analogs and substituted derivatives thereof;
safe and effective amounts of morphines, analogs and substituted derivatives thereof;
hyperpreserving amounts of polycarboxylic acid chelators, analogs and substituted derivatives thereof;
hyperpreserving amounts of resveratrol family members, analogs and substituted derivatives thereof;
safe and effective amounts of cysteine family members, analogs and substituted derivatives thereof; and
mixtures thereof.
-
-
322. A method for treating a disorder associated with an adrenergic receptor in a human or animal subject, comprising:
-
(a) administering to said subject a safe and effective amount of an adrenergic antagonist compound; and (b) administering to said subject a complement compound selected from the group consisting of;
hyperpreserving amounts of ascorbates, analogs and substituted derivatives thereof;
safe and effective amounts of opiates, analogs and substituted derivatives thereof;
hyperpreserving amounts of polycarboxylic acid chelators, analogs and substituted derivatives thereof;
hyperpreserving amounts of resveratrol family members, analogs and substituted derivatives thereof;
safe and effective amounts of cysteine family members, analogs and substituted derivatives thereof; and
mixtures thereof.
-
Specification